Format

Send to

Choose Destination
See comment in PubMed Commons below
Biomed Res Int. 2013;2013:826706. doi: 10.1155/2013/826706. Epub 2013 Mar 31.

Amylin uncovered: a review on the polypeptide responsible for type II diabetes.

Author information

1
Department of Biochemistry, School of Life Sciences, University of KwaZulu Natal, Westville Campus, Block F3, University Road, Private Bag X54001, Durban 4000, South Africa.

Abstract

Amylin is primarily responsible for classifying type II diabetes as an amyloid (protein misfolding) disease as it has great potential to aggregate into toxic nanoparticles, thereby resulting in loss of pancreatic β-cells. Although type II diabetes is on the increase each year, possibly due to bad eating habits of modern society, research on the culprit for this disease is still in its early days. In addition, unlike the culprit for Alzheimer's disease, amyloid β-peptide, amylin has failed to receive attention worthy of being featured in an abundance of review articles. Thus, the aim of this paper is to shine the spotlight on amylin in an attempt to put it onto the top of researchers' to-do list since the secondary complications of type II diabetes have far-reaching and severe consequences on public health both in developing and fully developed countries alike. This paper will cover characteristics of the amylin aggregates, mechanisms of toxicity, and a particular focus on inhibitors of toxicity and techniques used to assess these inhibitors.

PMID:
23607096
PMCID:
PMC3626316
DOI:
10.1155/2013/826706
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Support Center